No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ASND240517C115000
- 10.10
- -14.11-58.28%
15min DelayTrading May 14 14:34 ET
10.10High10.10Low
10.10Open24.21Pre Close12 Volume6 Open Interest115.00Strike Price12.12KTurnover0.00%IV0.09%PremiumMay 17, 2024Expiry Date12.99Intrinsic Value100Multiplier3DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma9.77Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Ascendis Pharma Says FDA Has Delayed TransCon PTH Review
Ascendis Pharma Says FDA Extending Review Period for NDA
By Ben Glickman Ascendis Pharma said regulators had pushed back the target action date for reviewing its hypoparathyroidism treatment after the company submitted additional information. The Danish b
UPDATE 1-FDA Extends Review of Ascendis Pharma's Hormone Disorder Therapy
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults With Hypoparathyroidism
- Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024 COPENHAGEN, Denmark, May 14, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function
Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism wi
Comments
See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...
7
2
Ascendis Pharma's high share price may risk investor returns as future revenue forecasts are less promising. While most investors are hopeful for a business turnaround, analysts are less confident.
1
Despite strong revenue growth, the stock's fall in price can be viewed negatively, possibly due to overly optimistic growth projections. The stock's current dip might offer a good entry point if it continues displaying signs of sustainable long-term growth.
QUICK SCALP 84 $ASND — STOCK & OPTION PLAY
ALERT ON: $84.00
ON THE WATCH: $84.11
🥇 SIGNED OF MORE UPTREND: $84.25
NEED IT TO BREAK OVER: $84.49
key indicator for MORE uptrend $84.69
confirmation uptrend - $84.72
mini breakout - $84.86
Next level of breakout: $84.98. $Ascendis Pharma A/S(ASND.US$
ALERT ON: $84.00
ON THE WATCH: $84.11
🥇 SIGNED OF MORE UPTREND: $84.25
NEED IT TO BREAK OVER: $84.49
key indicator for MORE uptrend $84.69
confirmation uptrend - $84.72
mini breakout - $84.86
Next level of breakout: $84.98. $Ascendis Pharma A/S(ASND.US$
1
QUICK SCALP 83 $ASND — STOCK & OPTION PLAY
ALERT ON: $83.09
ON THE WATCH: $83.16
🥇 SIGNED OF MORE UPTREND: $83.23
NEED IT TO BREAK OVER: $83.46
key indicator for MORE uptrend $83.59
confirmation uptrend - $83.68
mini breakout - $83.75
Prepare for a bigger breakout: $83.91 $Ascendis Pharma A/S(ASND.US$
ALERT ON: $83.09
ON THE WATCH: $83.16
🥇 SIGNED OF MORE UPTREND: $83.23
NEED IT TO BREAK OVER: $83.46
key indicator for MORE uptrend $83.59
confirmation uptrend - $83.68
mini breakout - $83.75
Prepare for a bigger breakout: $83.91 $Ascendis Pharma A/S(ASND.US$
Read more
baqklin : thanks
74349332 : what site do you get this informatiom from?